AstraZeneca PLC's slim hopes that its asthma drug Fasenra (benralizumab) could have a future as a treatment for chronic obstructive pulmonary disease have been dashed with the failure of a second Phase III trial in the space of just three weeks.
The company has announced top-line results from the TERRANOVA trial which reveal that Fasenra did not meet the primary endpoint...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)